News & Updates

Coming on the heels of the second interim analysis, the protocol-specified final invasive disease-free survival (iDFS) analysis of the phase III NATALEE trial continues to show a highly significant iDFS benefit with the combination of the CDK 4/6 inhibitor ribociclib and a nonsteroidal aromatase inhibitor (NSAI) in individuals with HR+/HER2- early breast cancer.

One in five young BRCA carriers with breast cancer subsequently conceive within 10 years, without any detrimental effect on disease-free survival, according to a study.

Second-line treatment with axicabtagene ciloleucel (axi-cel) or lisocabtagene maraleucel (liso-cel) helps improve survival in high-risk patients with diffuse large B-cell lymphoma (DLBCL), but both therapies are expensive, a study has shown.

In the final overall survival (OS) analysis of the phase III MONARCH 3 trial, the combination of the CDK 4/6 inhibitor abemaciclib and a nonsteroidal aromatase inhibitor (NSAI) continued to show clinically meaningful signals as first-line (1L) treatment for HR+/HER2- advanced breast cancer.

Dual positivity for alpha-fetoprotein (AFP) bound to Lens culinaris agglutinin (AFP-L3) ≥15 percent and des-gamma-carboxyprothrombin (DCP) ≥7.5 can strongly predict majority of early hepatocellular carcinoma (HCC) recurrences following liver transplantation (LT), suggests a study.

In the second interim analysis of the Asian cohort from the phase III MAGNITUDE study, a combination regimen comprising niraparib and abiraterone acetate plus prednisone (NIRA-AAP) improved clinical outcomes in patients with BRCA+ metastatic castration-resistant prostate cancer (mCRPC).

Updates from two MARIPOSA trials presented at ESMO Asia 2023 underpin the potential of amivantamab-based regimens for the treatment of locally advanced or metastatic EGFR-mutated non-small cell lung cancer (EGFRm NSCLC) in Asian subgroups.